

<b>Gender (n = 35)</b>	
Female	35 (100.0%)
Male	0 (0.0%)
<b>Cancer type (n = 35)</b>	
TNBC	28 (80.0%)
ER+	5 (14.3%)
HER2+	2 (5.7%)
<b>Treatment naïve (Yes/No) (n = 35)</b>	
Yes	14 (40.0%)
No	21 (60.0%)
<b>Tumor site (n = 35)</b>	
Primary	26 (74.3%)
Local recurrence	1 (2.9%)
Lymph node	4 (11.4%)
Pleural effusion	1 (2.9%)
Ascites	1 (2.9%)
Metastatic breast cancer	2 (5.7%)
<b>TMA PDX sample (n = 38)</b>	
Directly from patient	36 (95.0%) (two samples taken from MAN10 patient)
PDX residual disease after olaparib treatment	2 (5.0%)

**Supplementary Table 2.** Disease characteristics of breast cancer patients for PDX TMA samples (please see Figure 6C-6F).